Literature DB >> 24438955

Counterpoint: A tale of two meta-analyses revisited.

Erica D Dommasch1, Andrea B Troxel2, Joel M Gelfand3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24438955      PMCID： PMC4350774          DOI： 10.1016/j.jaad.2013.10.053

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   15.487


× No keyword cloud information.
  16 in total

1.  Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.

Authors:  Atsuyuki Igarashi; Takeshi Kato; Mai Kato; Michael Song; Hidemi Nakagawa
Journal:  J Dermatol       Date:  2011-09-29       Impact factor: 4.005

Review 2.  The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials.

Authors:  Craig Leonardi; Kim Papp; Bruce Strober; Kristian Reich; Akihiko Asahina; Yihua Gu; Joseph Beason; Stephen Rozzo; Stephen Tyring
Journal:  Am J Clin Dermatol       Date:  2011-10-01       Impact factor: 7.403

3.  A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.

Authors:  Kenneth B Gordon; Richard G Langley; Alice B Gottlieb; Kim A Papp; Gerald G Krueger; Bruce E Strober; David A Williams; Yihua Gu; Joaquin M Valdes
Journal:  J Invest Dermatol       Date:  2011-10-20       Impact factor: 8.551

4.  Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.

Authors:  B E Strober; J J Crowley; P S Yamauchi; M Olds; D A Williams
Journal:  Br J Dermatol       Date:  2011-07-28       Impact factor: 9.302

5.  Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.

Authors:  A B Gottlieb; C Leonardi; F Kerdel; S Mehlis; M Olds; D A Williams
Journal:  Br J Dermatol       Date:  2011-08-04       Impact factor: 9.302

6.  Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.

Authors:  Caitriona Ryan; Craig L Leonardi; James G Krueger; Alexa B Kimball; Bruce E Strober; Kenneth B Gordon; Richard G Langley; James A de Lemos; Yahya Daoud; Derek Blankenship; Salahuddin Kazi; Dan H Kaplan; Vincent E Friedewald; Alan Menter
Journal:  JAMA       Date:  2011-08-24       Impact factor: 56.272

7.  Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL).

Authors:  Tsen-Fang Tsai; Ji-Chen Ho; Michael Song; Philippe Szapary; Cynthia Guzzo; Yuang-Kuang Shen; Shu Li; Kwang-Joong Kim; Tae-Yoon Kim; Jee-Ho Choi; Jai-Il Youn
Journal:  J Dermatol Sci       Date:  2011-05-20       Impact factor: 4.563

8.  Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.

Authors:  Kim A Papp; Yves Poulin; Robert Bissonnette; Marc Bourcier; Darryl Toth; Leslie Rosoph; Melanie Poulin-Costello; Mike Setterfield; Jerry Syrotuik
Journal:  J Am Acad Dermatol       Date:  2010-09-17       Impact factor: 11.527

9.  A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

Authors:  Gerald G Krueger; Richard G Langley; Craig Leonardi; Newman Yeilding; Cynthia Guzzo; Yuhua Wang; Lisa T Dooley; Mark Lebwohl
Journal:  N Engl J Med       Date:  2007-02-08       Impact factor: 91.245

10.  Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

Authors:  K A Papp; C E M Griffiths; K Gordon; M Lebwohl; P O Szapary; Y Wasfi; D Chan; M-C Hsu; V Ho; P D Ghislain; B Strober; K Reich
Journal:  Br J Dermatol       Date:  2013-04       Impact factor: 9.302
View more
  1 in total

1.  Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.

Authors:  Marthe-Lisa Schaarschmidt; Christian Kromer; Raphael Herr; Astrid Schmieder; Diana Sonntag; Sergij Goerdt; Wiebke K Peitsch
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.